Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
Natacyn® (natamycin ophthalmic suspension) 5% is a sterile medication used topically in the eye to treat fungal infections. Each milliliter contains 50 mg of natamycin, an antifungal agent effective against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium, and Penicillium. The suspension also includes benzalkonium chloride 0.02% as a preservative, with sodium hydroxide and/or hydrochloric acid to adjust the pH, and purified water as inactive ingredients. Natamycin functions by binding to sterols in the fungal cell membrane, altering its permeability and leading to the depletion of essential cellular components, thereby exerting a fungicidal effect.
Fact Table | |
Formula | C33H47NO13 |
License | US FDA |
Bioavailability | Minimal (topical ophthalmic use) |
Legal status | Rx-only (prescription) |
Chemical Name | Natamycin |
Elimination half-life | Not systemically absorbed |
Dosage (Strength) | 5% (50 mg/mL) ophthalmic suspension |
Pregnancy | Category C – Consult a doctor |
Brands | Natacyn |
Protein binding | Not applicable (topical) |
PubChem CID | 5284447 |
MedlinePlus | a607058 |
ChEBI | 7515 |
ATC code | S01AA30 |
DrugBank | DB00826 |
KEGG | D08226 |
Routes of administration | Topical (ophthalmic) |
Shake the bottle well before use. For fungal keratitis, instill one drop of Natacyn into the conjunctival sac of the affected eye at hourly or two-hourly intervals. After the initial 3 to 4 days, the frequency can typically be reduced to one drop 6 to 8 times daily. Treatment should continue for 14 to 21 days or until the infection resolves. In cases of fungal blepharitis and conjunctivitis, an initial dosage of 4 to 6 daily applications may suffice. Always follow the specific instructions provided by your healthcare provider.
Active ingredient:
Inactive ingredients:
Natacyn is contraindicated in individuals with a known hypersensitivity to natamycin or any of the components of the formulation.
Topical Use Only: Natacyn is intended for topical ophthalmic use and should not be injected.Contact Lens Wearers: Patients exhibiting signs and symptoms of fungal eye infections should refrain from wearing contact lenses during treatment.
Pregnancy and Nursing: Natacyn should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised when administering to nursing mothers, as it is unknown whether natamycin is excreted in human milk.
Pediatric Use: The safety and effectiveness of Natacyn in pediatric patients have not been established.
General Precautions: If there is no improvement in keratitis after 7 to 10 days of treatment, re-evaluation is necessary to determine if the infection is caused by a non-susceptible organism.
The following adverse reactions have been reported during post-marketing use of Natacyn:
If you experience any of these side effects, contact your healthcare provider promptly.